Alterity Therapeutics Limited
Alterity Therapeutics Limited (ATHE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ATHE · as of Jun 9, 2026
Key Statistics
Explore Alterity Therapeutics Limited Data
athe stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
Competitors & Peers
athe competitorsATHE
ANVS
BTAI
DYAI
EVAX
GBIOStock Performance
Full HistoryAbout Alterity Therapeutics Limited
Alterity Therapeutics Limited an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntingt…
what is alterity therapeutics limited · athe stock overview · alterity therapeutics limited company profile · who is alterity therapeutics limited ceo · athe NASDAQ · alterity therapeutics limited headquarters · alterity therapeutics limited business segments
About Stock Overview & Key Data
Alterity Therapeutics Limited (ATHE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 29, 2003. As of the latest trading session, ATHE stock price is $3.92, with a market capitalization of $35.5M. The stock has returned -19.01% over the past 12 months and +27.27% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Alterity Therapeutics Limited stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Alterity Therapeutics Limited reported revenue of $5.4M and net income of -$12.1M. For detailed data — including Alterity Therapeutics Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Alterity Therapeutics Limited (ATHE) stock price is $3.92. The stock is traded on NASDAQ under the ticker symbol ATHE. The 52-week range is $2.66 – $7.00.